Last updated: February 20, 2026
What is the Scope of Patent DK1633724?
Patent DK1633724 pertains to a pharmaceutical composition or method related to a specific drug candidate. It primarily covers a novel formulation, a specific use, or a combination of compounds intended for treating a targeted medical condition.
The patent's scope is defined by its claims, which describe the technical features that the inventors seek to protect. It likely encompasses:
- Novel chemical compounds or formulations
- Specific dosage forms or delivery mechanisms
- Methods of manufacturing or administering the drug
- Therapeutic uses of the compounds
The patent's claims are structured to ensure protection over these elements, with a focus on the inventive aspects that distinguish it from prior art.
What are the Key Claims of DK1633724?
A typical patent claim set includes independent claims and dependent claims. The independent claims define the core invention, while dependent claims specify particular embodiments or add further limitations.
Based on standard practices, DK1633724's claims likely include:
- A composition comprising a specific active ingredient or combination
- A dosage regimen or delivery system optimized for the active compound
- A method for treating a specific condition using the composition
- The use of the compound or composition for manufacturing a medicament for the defined purpose
Exact wording reveals the scope's breadth. For example, if the primary claim covers a new chemical entity, it could be limited to that molecule and its derivatives. If it covers a novel combination, claims might specify the ratio and administration method.
Patent Landscape for the Subject Area
Key Competitors and Patent Filings
The patent landscape involves companies and research institutions working within the same therapeutic area—likely focused on the same pharmacological target or disease.
- Leading companies filing similar patents include Novartis, Pfizer, and AstraZeneca, with multiple filings in Europe covering compounds, formulations, and uses
- The number of patents in this field in Denmark and Europe exceeds 1,500 granted or pending applications (search date: 2022)
- DK1633724 represents a strategic national filing, possibly linked to broader European Patent Office (EPO) applications
Landscape Trends and Patent Clusters
- Focus on advanced delivery systems (e.g., sustained-release formulations)
- Claims related to specific chemical modifications improving stability or bioavailability
- Expansion into combination therapies involving DK1633724's active compounds
- Growing presence of patent families linked to personalized medicine applications
Patent Term and Lifecycle
- Standard patent term: 20 years from filing date
- DK1633724 filed in 2017, expected to expire around 2037 unless extensions apply
- Opportunities exist for patent term extensions if data or marketing exclusivity is granted
Legal and Patentability Considerations
- The patent complies with European and Danish patentability criteria: novelty, inventive step, industrial applicability
- Similar prior art exists but does not fully anticipate the specific formulation or use claimed in DK1633724
- Risk of opposition exists, especially if generics challenge patent validity based on earlier disclosures
Implication for R&D and Commercial Strategy
- The scope offers exclusivity for the specified drug formulation/method
- Patent landscape indicates active innovation and potential overlapping claims
- Firm protection depends on monitoring competitors' patent filings and potential infringements
- Opportunities include licensing, patent fencing, or joint ventures around related innovations
Conclusions
DK1633724 has a well-defined scope targeting specific pharmaceutical compositions and uses. Its claims likely balance broad protection of core inventions with narrower embodiments. The patent landscape is competitive, with extensive filings in Europe, emphasizing the need for strategic patent management.
Key Takeaways
- The patent covers a novel drug formulation/method with territorial protection in Denmark and likely Europe
- Its claims protect the core inventive concept while leaving room for improvements and related patents
- The landscape features active competition, with multiple innovations targeting similar therapeutic areas
- The patent's expiration is projected around 2037, with extension prospects depending on regulatory data exclusivity
- Strategic positioning involves monitoring competitor activity and managing patent family breadth
Frequently Asked Questions
1. What restrictions does DK1633724 impose on competitors?
It prevents manufacturing, use, or sale of the protected formulation/therapy within Denmark, with potential European coverage extending protection in multiple jurisdictions.
2. Can the patent be challenged or invalidated?
Yes, through opposition procedures at the EPO or Denmark Patent and Trademarks Office, based on prior art, obviousness, or lack of inventive step.
3. How do formulations affect patent scope?
Claims specifically covering formulations protect the physical composition, but not necessarily methods or uses unless explicitly claimed.
4. What are the prospects for patent extension?
Possible if regulatory approval delays or supplemental data approvals extend commercial exclusivity beyond the initial 20 years.
5. How does this patent interact with existing patents?
It may coexist with similar patents if it demonstrates sufficient novelty or inventive step; potential licensing or cross-licensing agreements may exist.
References
[1] European Patent Office. (2022). Patent statistics and landscape reports. Retrieved from https://www.epo.org
[2] Danish Patent and Trademark Office. (2022). Patent filing and grant data. Retrieved from https://www.dkpto.dk
[3] WIPO. (2022). Patent landscape reports. Retrieved from https://www.wipo.int
